FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gary Schwartz

Research Profile

Chemicals & Drugs

Procedures

Antineoplastic Combined Chemotherapy Protocols

Disorders

Concepts & Ideas

Anatomy

Tumor Cells, Cultured

Physiology

Co-author Network

Publications

TOP 3
Jason J Luke; Gary K Schwartz
Chemotherapy in the management of advanced cutaneous malignant melanoma.
Grazia Ambrosini; Elisa de Stanchina; Alan L. Ho; Elgilda Musi; Gary K Schwartz
Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death.
Jayasree S Nair; Alan L. Ho; Tahir Sheikh; Gary K Schwartz
PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gary Schwartz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jason J Luke; Gary K Schwartz
Chemotherapy in the management of advanced cutaneous malignant melanoma.
Clinics in dermatology 2013;31(3):290-7.
2013: Grazia Ambrosini; Elisa de Stanchina; Alan L. Ho; Elgilda Musi; Gary K Schwartz
Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death.
Molecular cancer therapeutics 2013;12(5):768-76.
2013: Jayasree S Nair; Alan L. Ho; Tahir Sheikh; Gary K Schwartz
PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
Anticancer research 2013;33(4):1307-16.
2013: Gary K Schwartz; William D Tap; Samir D Undevia; Brian A Van Tine; Shyamprasad Deraje Vasudeva; Vincent Yim; Scott H Okuno; Li-Xuan Qin; Damon R Reed; Petra Rietschel; Scott M Schuetze; Abdul Abdullah; Douglas Adkins; Mark Agulnik; Cristina R Antonescu; Christiana Bitas; Bruce E Brockstein; Helen X Chen; Bartosz Chmielowski; Mercedes Condy; Mark A Dickson; L Austin Doyle; Alan L. Ho; Vicki Keedy; Andrew S Kraft; Michael B Livingston; Joseph A Ludwig; ROBERT G MAKI
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
The lancet oncology 2013;14(4):371-82.
2013: Mark A Dickson; David J Kwiatkowski; Cristina R Antonescu; Gary K Schwartz; Izabela Malinowska Kolodziej
Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
International journal of cancer. Journal international du cancer 2013;132(7):1711-7.
2013: Gary K Schwartz; Paul K Stockman; David Wilson; Ozlem Ataman; Richard Carvajal; Shampa Das; Rachel Midgley; Scott J Rodig; Geoffrey I Shapiro
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Investigational new drugs 2013;31(2):370-80.
2013: John F Gerecitano; Dennis Huszar; Nancy L Lewis; Jianguo Li; Anna Osmukhina; Jeffrey M Skolnik; Joe J Stephenson; Kaida Wu; Zhiping You; Gary K Schwartz
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
Investigational new drugs 2013;31(2):355-62.
2013: ROBERT G MAKI; Lloyd J Old; Erika Ritter; Rita Chiu; David R D'Adamo; Sacha Gnjatic; Achim A Jungbluth; Jennifer Kachel; Mary-Louise Keohan; Israel Lowy; Kelly Scheu; Gary K Schwartz; Michael J Wagner; Gerd Ritter
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.
Sarcoma 2013;2013():168145.
2013: Mark Dickson; Mary-Louise Keohan; ROBERT G MAKI; S H Okuno; T J Akhurst; Cristina R Antonescu; David R D'Adamo; Gary K Schwartz
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(1):252-7.
2012: Xi Chen; Lisa M DeAngelis; Thomas Kaley; Gary K Schwartz; Richard D Carvajal
Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.
Neurology 2012;79(18):1929-31.
2012: Heather J Landau; Samuel C McNeely; Jayasree S Nair; Stephen D Nimer; Takashi Asai; Raymond L Comenzo; Hillel Friedman; Suresh C Jhanwar; Gary K Schwartz
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Molecular cancer therapeutics 2012;11(8):1781-8.
2012: Mrinal M Gounder; Gary K Schwartz
Moving forward one Notch at a time.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(19):2291-3.
2012: Grazia Ambrosini; Richard Carvajal; Christine A Pratilas; Li-Xuan Qin; Oliver Surriga; Madhavi Tadi; Gary K Schwartz
Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(13):3552-61.
2012: Jason J Luke; ROBERT G MAKI; Elgilda Musi; Richard Carvajal; David R D'Adamo; Elisa de Stanchina; Mark Dickson; Mary-Louise Keohan; Samuel Singer; Gary K Schwartz
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2638-47.
2012: Jayasree S Nair; Alan L. Ho; Gary K Schwartz
The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.
Cell cycle (Georgetown, Tex.) 2012;11(4):807-17.
2012: Keith T Flaherty; Patricia M LoRusso; Peter J O'Dwyer; Sophia S Randolph; Vandana G Abramson; Rachel Courtney; Angela Demichele; M Naveed Shaik; Keith D Wilner; Gary K Schwartz
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):568-76.
2012: Alan L. Ho; Elgilda Musi; Jayasree S Nair; Grazia Ambrosini; Elisa de Stanchina; Shyamprasad Deraje Vasudeva; Gary K Schwartz
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
PloS one 2012;7(7):e40439.
2011: Moses M Darpolor; Peter T Kennealey; Ellen Ackerstaff; Jin-Hong Chen; Hongbiao Carl Le; Asif Rizwan; Elliot B Sambol; Gary K Schwartz; Samuel Singer; Kristen L Zakian; Jason A Koutcher
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
NMR in biomedicine 2011;24(9):1159-68.
2011: Mark Andrew Dickson; Mithat Gonen; Steven Grant; Robert A Lefkowitz; Renee M McGovern; Dana E Rathkopf; Joel M Reid; John D Roberts; Matthew M Ames; Lauren M Cane; Richard Carvajal; Heather J Dials; Gary K Schwartz
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
Investigational new drugs 2011;29(5):1004-12.
2011: Emanuela Romano; Gary K Schwartz; Jedd D Wolchock; Paul B Chapman; Richard D Carvajal
Treatment implications of the emerging molecular classification system for melanoma.
The lancet oncology 2011;12(9):913-22.
2011: Patrick Y Wen; W K Alfred Yung; Tracy T Batchelor; Bruce A Chabner; Susan M Chang; Timothy F Cloughesy; John F de Groot; Keith Flaherty; Evanthia Galanis; Mark R Gilbert; Stuart A Grossman; Minesh Mehta; David Peereboom; Michael D Prados; David A Reardon; David Schiff; Gary K Schwartz; Lisa M DeAngelis
It is time to include patients with brain tumors in phase I trials in oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(24):3211-3.
2011: Richard Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold B Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
KIT as a therapeutic target in metastatic melanoma.
JAMA : the journal of the American Medical Association 2011;305(22):2327-34.
2011: Gary K Schwartz; M N Shaik; K D Wilner; S S Randolph; R Courtney; Mark Dickson; Patricia M LoRusso; P J O'Dwyer
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
British journal of cancer 2011;104(12):1862-8.
2011: Mrinali Patel; Elizabeth Smyth; Paul B Chapman; Jedd D Wolchok; Gary K Schwartz; David H Abramson; Richard Carvajal
Therapeutic implications of the emerging molecular biology of uveal melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2087-100.
2011: Mark Dickson; Richard Carvajal; Alfred H Merrill; Mithat Gonen; Lauren M Cane; Gary K Schwartz
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2484-92.
2010: Mark Dickson; Manish A Shah; Dana Elizabeth Rathkopf; Archie N Tse; Richard Carvajal; Nian Wu; Robert A Lefkowitz; Mithat Gonen; Lauren M Cane; Heather J Dials; Gary K Schwartz
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Cancer chemotherapy and pharmacology 2010;66(6):1113-21.
2010: Jeffrey D Wessler; Richard M Steingart; Gary K Schwartz; Ben-Gary Harvey; Wendy Lynn Schaffer
Dramatic improvement in pulmonary hypertension with rapamycin.
Chest 2010;138(4):991-3.
2010: Brian A Ginsberg; Humilidad F Gallardo; Teresa S Rasalan; Matthew Adamow; Zhenyu Mu; Sapna Tandon; Barrett B Bewkes; Ruth-Ann Roman; Paul B Chapman; Gary K Schwartz; Richard Carvajal; Katherine S Panageas; Stephanie L Terzulli; Alan N Houghton; Jianda D Yuan; Jedd D Wolchok
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(15):4057-65.
2010: Jordi Barretina; Barry S Taylor; Shantanu Banerji; Alexis H Ramos; Mariana Lagos-Quintana; Penelope L Decarolis; Kinjal Shah; Nicholas D Socci; Barbara A Weir; Alan Ho; Derek Y Chiang; Boris Reva; Craig H Mermel; Gad Getz; Yevgenyi Antipin; Rameen Beroukhim; John E Major; Charles Hatton; Richard Nicoletti; Megan Hanna; Ted Sharpe; Tim J Fennell; Kristian Cibulskis; Robert C Onofrio; Tsuyoshi Saito; Neerav Shukla; Christopher Lau; Sven Nelander; Serena J Silver; Carrie Sougnez; Agnes Viale; Wendy Winckler; ROBERT G MAKI; Levi A Garraway; Alex E Lash; Heidi Greulich; David E Root; William R Sellers; Gary K Schwartz; Cristina R Antonescu; Eric S Lander; Harold E Varmus; Marc Ladanyi; Chris Sander; Matthew Meyerson; Samuel Singer
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
Nature genetics 2010;42(8):715-21.
2010: Mihai Hajdu; Samuel Singer; ROBERT G MAKI; Gary K Schwartz; Mary-Louise Keohan; Cristina R Antonescu
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting.
The Journal of pathology 2010;221(3):300-7.
2010: Kosalaram Goteti; C Edwin Garner; Lucas Utley; Jing Dai; Susan Ashwell; Demetri T Moustakas; Mithat Gonen; Gary K Schwartz; Steven E Kern; Sonya Zabludoff; Patrick J Brassil
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Cancer chemotherapy and pharmacology 2010;66(2):245-54.
2010: Geoffrey Y Ku; Jianda Yuan; David B Page; Sebastian E A Schroeder; Katherine S Panageas; Richard Carvajal; Paul B Chapman; Gary K Schwartz; James P Allison; Jedd D Wolchok
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Cancer 2010;116(7):1767-75.
2010: David Boss; Gary K Schwartz; M R Middleton; D D Amakye; H Swaisland; R S Midgley; M Ranson; S Danson; Hilary Calvert; R Plummer; C Morris; Richard Carvajal; L R Chirieac; J H M Schellens; G I Shapiro
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(4):884-94.
2010: Samuel McNeely; Chiara Conti; Tahir Sheikh; Himali Patel; Sonya Zabludoff; Yves Pommier; Gary K Schwartz; Archie Tse
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
Cell cycle (Georgetown, Tex.) 2010;9(5):995-1004.
2009: Dana Elizabeth Rathkopf; Mark Dickson; Darren R Feldman; Richard Carvajal; Manish A Shah; Nian Wu; Robert Lefkowitz; Mithat Gonen; Lauren M Cane; Heather J Dials; Jennifer L Winkelmann; George J Bosl; Gary K Schwartz
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7405-11.
2009: Grazia Ambrosini; Sharon L Seelman; Gary K Schwartz
Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation.
Cancer research 2009;69(15):6115-21.
2009: William P Tew; Delia Radovich; Eileen O'Reilly; Gary K Schwartz; Deborah Schrag; Leonard B Saltz; David P Kelsen; Stacey Kepler; David H Ilson
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Investigational new drugs 2009;27(4):366-73.
2009: ROBERT G MAKI; David R D'Adamo; Mary-Louise Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee Hensley; Monica Mita; Chris H Takimoto; Andrew Kraft; Anthony D Elias; Bruce E Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3133-40.
2009: Suzanne George; Priscilla Merriam; ROBERT G MAKI; Annick D Van den Abbeele; Jeffrey T Yap; Timothy Akhurst; David C Harmon; Gauri Bhuchar; Margaret M O'Mara; David R D'Adamo; Jeffrey Morgan; Gary K Schwartz; Andrew J Wagner; James E Butrynski; George D Demetri; Mary-Louise Keohan
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3154-60.
2009: Gary K Schwartz; Kathryn Winter; Bruce D Minsky; Christopher Crane; P John Thomson; Pramila Anne; Howard Gross; Christopher Willett; David P Kelsen
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(12):1956-62.
2009: Jayasree S Nair; Alan L. Ho; Archie N Tse; Jesse Coward; Haider Cheema; Grazia Ambrosini; Nicholas Keen; Gary K Schwartz
Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.
Molecular biology of the cell 2009;20(8):2218-28.
2009: Jayasree S Nair; Elisa de Stanchina; Gary K Schwartz
The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(6):2022-30.
2009: Mark Dickson; Gary K Schwartz
Development of cell-cycle inhibitors for cancer therapy.
Current oncology (Toronto, Ont.) 2009;16(2):36-43.
2009: Chandima S K Rajapakse; Alberto Martínez; Becky Naoulou; Andrzej A Jarzecki; Liliana Suárez; Christiane Deregnaucourt; Véronique Sinou; Joseph Schrével; Elgilda Musi; Grazia Ambrosini; Gary K Schwartz; Roberto A Sánchez-Delgado
Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine.
Inorganic chemistry 2009;48(3):1122-31.
2009: Jesse Coward; Grazia Ambrosini; Elgilda Musi; Jean-Philip Truman; Adriana Haimovitz-Friedman; Jeremy C Allegood; Elaine Wang; Alfred H Merrill; Gary K Schwartz
Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway.
Autophagy 2009;5(2):184-93.
2009: Raymond De Meng; Christopher C Shelton; Yueming Li; Li-Xuan Qin; Daniel A Notterman; Philip B Paty; Gary K Schwartz
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
Cancer research 2009;69(2):573-82.
2009: Sheron Latcha; ROBERT G MAKI; Gary K Schwartz; Carlos D Flombaum
Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis.
Sarcoma 2009;2009():575629.
2009: Richard Carvajal; Archie N Tse; Manish A Shah; Robert A Lefkowitz; Mithat Gonen; Lisa Gilman-Rosen; Jeremy Kortmansky; David P Kelsen; Gary K Schwartz; Eileen O'Reilly
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2009;9(4):404-9.
2009: Archie N Tse; Tahir N Sheikh; Ho Alan; Ting-Chao Chou; Gary K Schwartz
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Molecular pharmacology 2009;75(1):124-33.
2008: Archie N Tse; David S Klimstra; Mithat Gonen; Manish A Shah; Tahir Sheikh; Rachel Sikorski; Richard Carvajal; Janet Mui; Caroll Tipian; Eileen O'Reilly; Ki Young Chung; ROBERT G MAKI; Robert Lefkowitz; Karen T Brown; Katia Manova-Todorova; Nian Wu; Merrill J Egorin; David P Kelsen; Gary K Schwartz
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6704-11.
2008: Geoffrey Y Ku; David H Ilson; Lawrence H Schwartz; Marinela Capanu; Eileen O'Reilly; Manish A Shah; David P Kelsen; Gary K Schwartz
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.
Cancer chemotherapy and pharmacology 2008;62(5):875-80.
2008: Sonya Zabludoff; Chun Deng; Michael R Grondine; Adam M Sheehy; Susan Ashwell; Benjamin L Caleb; Stephen Green; Heather R Haye; Candice L Horn; James Janetka; Dongfang Liu; Elizabeth Mouchet; Shannon Ready; Judith L Rosenthal; Christophe Queva; Gary K Schwartz; Karen J Taylor; Archie N Tse; Graeme E Walker; Anne M White
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Molecular cancer therapeutics 2008;7(9):2955-66.
2008: Grazia Ambrosini; Haider S Cheema; Sharon Seelman; Allison Teed; Elliot B Sambol; Samuel Singer; Gary K Schwartz
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Molecular cancer therapeutics 2008;7(4):890-6.
2008: Grazia Ambrosini; Sharon L Seelman; Li-Xuan Qin; Gary K Schwartz
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Cancer research 2008;68(7):2312-20.
2008: Igor Matushansky; Eva Hernando; Nicholas D Socci; Tulio Matos; Joslyn Mills; Mark A Edgar; Gary K Schwartz; Samuel Singer; Carlos Cordon-Cardo; ROBERT G MAKI
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas.
The American journal of pathology 2008;172(4):1069-80.
2008: A Duffy; Jeremy Kortmansky; Gary K Schwartz; Marinela Capanu; S Puleio; B Minsky; Leonard B Saltz; David P Kelsen; Eileen O'Reilly
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(1):86-91.
2007: Monica Fornier; Dana Elizabeth Rathkopf; Manish A Shah; Sujata M Patil; Eileen O'Reilly; Archie N Tse; Clifford Hudis; Robert Lefkowitz; David P Kelsen; Gary K Schwartz
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5841-6.
2007: Tianhua Guo; Narasimhan P Agaram; Grace C Wong; Glory Hom; David R D'Adamo; ROBERT G MAKI; Gary K Schwartz; Darren R Veach; Bayard Clarkson; Samuel Singer; Ronald P DeMatteo; Peter Besmer; Cristina R Antonescu
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4874-81.
2007: Samuel Singer; Nicholas D Socci; Grazia Ambrosini; Elliot B Sambol; Penelope DeCarolis; Yuhsin Wu; Rachael O'Connor; ROBERT G MAKI; Agnes Viale; Chris Sander; Gary K Schwartz; Cristina R Antonescu
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.
Cancer research 2007;67(14):6626-36.
2007: Grazia Ambrosini; Elliot B Sambol; Daisy Carvajal; Lyubomir T Vassilev; Samuel Singer; Gary K Schwartz
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Oncogene 2007;26(24):3473-81.
2007: Archie N Tse; Richard Carvajal; Gary K Schwartz
Targeting checkpoint kinase 1 in cancer therapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):1955-60.
2007: Archie N Tse; Katherine G Rendahl; Tahir Sheikh; Haider Cheema; Kim Aardalen; Millicent Embry; Sylvia Ma; Edward J Moler; Zhi Jie Ni; Daniel E Lopes de Menezes; Barbara Hibner; Thomas G Gesner; Gary K Schwartz
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):591-602.
2006: Richard Carvajal; Archie N Tse; Gary K Schwartz
Aurora kinases: new targets for cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):6869-75.
2006: Manish A Shah; Ramesh K Ramanathan; David H Ilson; Alissa Levnor; David R D'Adamo; Eileen O'Reilly; Archie N Tse; Robin Trocola; Lawrence H Schwartz; Marinela Capanu; Gary K Schwartz; David P Kelsen
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(33):5201-6.
2006: Elliot B Sambol; Grazia Ambrosini; Rula C Geha; Peter T Kennealey; Penelope DeCarolis; Rachael O'Connor; Yuhsin V Wu; Monica Motwani; Jin-Hong Chen; Gary K Schwartz; Samuel Singer
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Cancer research 2006;66(11):5858-66.
2006: Lawrence H Schwartz; Jane Colville; Michelle S Ginsberg; Liang Wang; Madhu Mazumdar; John Kalaigian; Hedvig Hricak; David H Ilson; Gary K Schwartz
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(6):1018-23.
2005: Gary K Schwartz; Manish A Shah
Targeting the cell cycle: a new approach to cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9408-21.
2005: David R D'Adamo; Sibyl E Anderson; Karen H Albritton; Jennifer Yamada; Elyn Riedel; Kelly Scheu; Gary K Schwartz; Helen Chen; ROBERT G MAKI
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7135-42.
2005: Gary K Schwartz; Aaron Weitzman; Eileen O'Reilly; Les Brail; Dinesh P de Alwis; Ann Cleverly; Barbara Barile-Thiem; Vincent P Vinciguerra; Daniel R Budman
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5365-73.
2005: Ghassan K Abou-Alfa; Eric K Rowinsky; Yehuda Z Patt; Gary K Schwartz; David P Kelsen; Sunil Sharma; Eve Siegel; Carlos R Becerra; S Gail Eckhardt; Kevie Feit; Robert L De Jager; Eileen O'Reilly
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
American journal of clinical oncology 2005;28(4):334-9.
2005: Gary K Schwartz
Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(20):4499-508.
2005: Manish A Shah; Jeremy Kortmansky; Monica Motwani; Marija Drobnjak; Mithat Gonen; Sandy Yi; Amanda Weyerbacher; Carlos Cordon-Cardo; Robert Lefkowitz; Baruch Brenner; Eileen O'Reilly; Leonard B Saltz; William Tong; David P Kelsen; Gary K Schwartz
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3836-45.
2005: Manish A Shah; Nancy Kemeny; Amanda J Hummer; Marija Drobnjak; Monica Motwani; Carlos Cordon-Cardo; Mithat Gonen; Gary K Schwartz
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3296-302.
2005: ROBERT G MAKI; Andrew Kraft; Kelly Scheu; Jennifer Yamada; Scott Wadler; Cristina R Antonescu; John J Wright; Gary K Schwartz
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Cancer 2005;103(7):1431-8.
2005: Jeremy Kortmansky; Manish A Shah; Andreas Kaubisch; Amanda Weyerbacher; Sandy Yi; William Tong; Rebecca Sowers; Mithat Gonen; Eileen O'Reilly; Nancy Kemeny; David H Ilson; Leonard B Saltz; ROBERT G MAKI; David P Kelsen; Gary K Schwartz
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1875-84.
2005: Ki Young Chung; Jinru Shia; Nancy Kemeny; Manish A Shah; Gary K Schwartz; Archie N Tse; Audrey Hamilton; Dorothy Pan; Deborah Schrag; Lawrence H Schwartz; David S Klimstra; Daniel Fridman; David P Kelsen; Leonard B Saltz
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1803-10.
2005: Manish A Shah; Gary K Schwartz
Cyclin-dependent kinases as targets for cancer therapy.
Cancer chemotherapy and biological response modifiers 2005;22():135-62.
2004: Harvey G Moore; Jinru Shia; David S Klimstra; Leyo Ruo; Madhu Mazumdar; Gary K Schwartz; Bruce D Minsky; Leonard B Saltz; Jose G Guillem
Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome.
Annals of surgical oncology 2004;11(11):955-61.
2004: Archie N Tse; Gary K Schwartz
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Cancer research 2004;64(18):6635-44.
2004: Manish A Shah; Gary K Schwartz
Treatment of metastatic esophagus and gastric cancer.
Seminars in oncology 2004;31(4):574-87.
2004: Eric Sherman; David M Rubin; Venkatraman E Seshan; Gary K Schwartz; Vincent A Miller; Mark Radzyner; Hirsch S Ruchlin; David Spriggs; David G Pfister
Using patients as their own controls for cost evaluation of phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1308-14.
2004: Gary K Schwartz; Joseph Bertino; Nancy Kemeny; Leonard B Saltz; David P Kelsen; William Tong; Mary Welch; Sandra Endres; Isaiah Dimery
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer.
Anti-cancer drugs 2004;15(3):219-27.
2003: Christoph Jung; Monica Motwani; Jeremy Kortmansky; Francis M Sirotnak; Yuhong She; Mithat Gonen; Adriana Haimovitz-Friedman; Gary K Schwartz
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):6052-61.
2003: Monica Motwani; Carina Rizzo; Francis M Sirotnak; Yuhong She; Gary K Schwartz
Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.
Molecular cancer therapeutics 2003;2(6):549-55.
2003: Manish A Shah; Gary K Schwartz
Cyclin-dependent kinases as targets for cancer therapy.
Cancer chemotherapy and biological response modifiers 2003;21():145-70.
2003: Jeremy Kortmansky; Gary K Schwartz
Bryostatin-1: a novel PKC inhibitor in clinical development.
Cancer investigation 2003;21(6):924-36.
2003: Michel Ducreux; Claus-Henning Köhne; Gary K Schwartz; Udo Vanhoefer
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14 Suppl 2():ii17-23.
2002: Garrett M Nash; Leonard B Saltz; Nancy Kemeny; Bruce D Minsky; Sunil Sharma; Gary K Schwartz; David H Ilson; Eileen O'Reilly; David P Kelsen; Daniel R Nathanson; Martin R Weiser; Jose G Guillem; Douglas Wong; Alfred M Cohen; Philip B Paty
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease.
Annals of surgical oncology 2002;9(10):954-60.
2002: Monica Motwani; Francis M Sirotnak; Yuhong She; Thérèse Commes; Gary K Schwartz
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Cancer research 2002;62(14):3950-5.
2002: Gary K Schwartz; Eileen O'Reilly; David H Ilson; Leonard B Saltz; Sunil Sharma; William Tong; Peter Maslak; Maxine Stoltz; Larry Eden; Pam Perkins; Sandra Endres; John Barazzoul; David Spriggs; David P Kelsen
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2157-70.
2002: Gary K Schwartz
CDK inhibitors: cell cycle arrest versus apoptosis.
Cell cycle (Georgetown, Tex.) 2002;1(2):122-3.
2002: David G Pfister; John McCaffrey; Andrew J Zahalsky; Gary K Schwartz; Eric Lis; William Gerald; Andrew G Huvos; Jatin P Shah; Dennis H Kraus; Ashok R Shaha; Bhuvanesh Singh; Suzanne L Wolden; Michael J Zelefsky; Ilana Palgi
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Investigational new drugs 2002;20(1):123-7.
2001: Alfred T Culliford; Ari D Brooks; Sunil Sharma; Leonard B Saltz; Gary K Schwartz; Eileen O'Reilly; David H Ilson; Nancy Kemeny; David P Kelsen; Jose G Guillem; Douglas Wong; Alfred M Cohen; Philip B Paty
Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer.
Annals of surgical oncology 2001;8(10):787-95.
2001: Monica Motwani; C Jung; Francis M Sirotnak; Yuhong She; Manish A Shah; Mithat Gonen; Gary K Schwartz
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):4209-19.
2001: Sunil Sharma; Nancy Kemeny; Gary K Schwartz; David P Kelsen; Eileen O'Reilly; David H Ilson; John Coyle; Robert L De Jager; M P Ducharme; S Kleban; Ellen M Hollywood; Leonard B Saltz
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3963-70.
2001: C P Jung; Monica Motwani; Gary K Schwartz
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2527-36.
2001: Manish A Shah; Gary K Schwartz
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2168-81.
2001: Gary K Schwartz; David H Ilson; Leonard B Saltz; Eileen O'Reilly; William Tong; Peter Maslak; J Werner; P Perkins; M Stoltz; David P Kelsen
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):1985-92.
2001: Chung-Tsen Hsueh; Y C Wu; Gary K Schwartz
UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):669-74.
2001: Eileen O'Reilly; KE Stuart; PM Sanz-Altamira; Gary K Schwartz; CM Steger; L Raeburn; Nancy Kemeny; David P Kelsen; Leonard B Saltz
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
Cancer 2001;91(1):101-5.
2000: X K Li; Monica Motwani; William Tong; William G Bornmann; Gary K Schwartz
Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells.
Molecular pharmacology 2000;58(6):1287-93.
2000: Andreas Kaubisch; Gary K Schwartz
Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Cancer journal (Sudbury, Mass.) 2000;6(4):192-212.
2000: Jason A Koutcher; Monica Motwani; Kristen L Zakian; X K Li; Cornelia Matei; Jonathan P Dyke; Douglas Ballon; Hyok-Hee Yoo; Gary K Schwartz
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1498-507.
2000: Monica Motwani; X Li; Gary K Schwartz
Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):924-32.
2000: Chung-Tsen Hsueh; Chang-Fang Chiu; David P Kelsen; Gary K Schwartz
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis.
Cancer chemotherapy and pharmacology 2000;45(5):389-96.
1999: F Fata; Eileen O'Reilly; David H Ilson; David G Pfister; D Leffel; David P Kelsen; Gary K Schwartz; Ephraim S Casper
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face.
Cancer 1999;86(10):2034-7.
1999: David H Ilson; Leonard B Saltz; Peter C Enzinger; Y Huang; Alice B Kornblith; Marc J Gollub; Eileen O'Reilly; Gary K Schwartz; J DeGroff; G Gonzalez; David P Kelsen
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3270-5.
1999: Monica Motwani; TM Delohery; Gary K Schwartz
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1876-83.
1999: Gary K Schwartz; A Harstrick; M González Barón
Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.
European journal of cancer (Oxford, England : 1990) 1999;35 Suppl 1():S9-13.
1998: Leonard B Saltz; David Spriggs; Larry J Schaaf; Gary K Schwartz; David H Ilson; Nancy Kemeny; J Kanowitz; CM Steger; M Eng; P Albanese; D Semple; CK Hanover; Gary L Elfring; Langdon L Miller; David P Kelsen
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3858-65.
1998: W David Jarvis; FA Fornari; Robert M Tombes; R K Erukulla; R Bittman; Gary K Schwartz; Paul Dent; Steven Grant
Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.
Molecular pharmacology 1998;54(5):844-56.
1998: Richard M Terek; Gary K Schwartz; K Devaney; L Glantz; Solida Mak; John Healey; José Pereira Albino
Chemotherapy and P-glycoprotein expression in chondrosarcoma.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society 1998;16(5):585-90.
1998: Chung-Tsen Hsueh; David P Kelsen; Gary K Schwartz
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(9):2201-6.
1998: Amreen Husain; N Rosales; Gary K Schwartz; David Spriggs
Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).
Gynecologic oncology 1998;70(1):17-22.
1998: Y Yokoyama; T Ito; V Hanson; Gary K Schwartz; A A Aderem; J F Holland; T Tamaya; T Ohnuma
PMA-induced reduction in invasiveness is associated with hyperphosphorylation of MARCKS and talin in invasive bladder cancer cells.
International journal of cancer. Journal international du cancer 1998;75(5):774-9.
1998: Alessia Donadio; K H Dragnev; Gary K Schwartz
Thymoma associated with syndrome of inappropriate antidiuretic hormone secretion and myasthenia gravis.
Southern medical journal 1998;91(3):278-9.
1998: F Costa; Gary K Schwartz; David P Kelsen
Adjuvant chemotherapy in gastric adenocarcinomas.
Cancer treatment and research 1998;98():41-63.
1998: Ephraim S Casper; RJ Waltzman; Gary K Schwartz; A Sugarman; David G Pfister; David H Ilson; James M Woodruff; Denis Leung; Joseph R Bertino
Phase II trial of paclitaxel in patients with soft-tissue sarcoma.
Cancer investigation 1998;16(7):442-6.
1997: Z Siprashvili; Gabriella Sozzi; Larry D Barnes; Peter McCue; Angela K Robinson; V Eryomin; L Sard; Elda Tagliabue; Angela Greco; L Fusetti; Gary K Schwartz; Marco A Pierotti; Carlo M Croce; Kay Huebner
Replacement of Fhit in cancer cells suppresses tumorigenicity.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(25):13771-6.
1997: Leonard B Saltz; Gary K Schwartz; David H Ilson; V Quan; David P Kelsen
A phase II study of topotecan administered five times daily in patients with advanced gastric cancer.
American journal of clinical oncology 1997;20(6):621-5.
1997: A König; Gary K Schwartz; Ramzi M Mohammad; Ayad Al-Katib; JL Gabrilove
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.
Blood 1997;90(11):4307-12.
1997: A Husain; X J Yan; N Rosales; Carol Aghajanian; Gary K Schwartz; David Spriggs
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2089-97.
1997: K Hayashi; Ralf Metzger; Dennis Salonga; Kathleen D Danenberg; Lawrence Leichman; U Fink; A Sendler; David P Kelsen; Gary K Schwartz; Susan Groshen; H J Lenz; Peter V Danenberg
High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach.
Oncogene 1997;15(12):1481-8.
1997: Gary K Schwartz; K Farsi; Peter Maslak; David P Kelsen; David Spriggs
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1467-72.
1997: JD Cunningham; Gary K Schwartz; M Karpeh; M Blundell; D P Kelson; Suresh C Jhanwar; José Pereira Albino
Loss of heterozygosity and homozygous deletion of the tpr locus in human gastric cancer.
American journal of surgery 1997;173(6):521-2.
1997: Ephraim S Casper; Gary K Schwartz; A Sugarman; Denis Leung; Murray F Brennan
Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):2111-7.
1997: Gary K Schwartz; D Ward; Leonard B Saltz; Ephraim S Casper; T Spiess; E Mullen; J Woodworth; R Venuti; P Zervos; A M Storniolo; David P Kelsen
A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(4):537-43.
1997: David P Kelsen; D Martin; J O'Neil; Gary K Schwartz; Leonard B Saltz; M T Sung; R von Borstel; Joseph Bertino
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1511-7.
1997: Daniel S Martin; Gary K Schwartz
Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade.
Oncology research 1997;9(1):1-5.
1996: Gary K Schwartz; K Christman; Leonard B Saltz; E Casper; V Quan; J Bertino; Daniel S Martin; J Colofiore; David P Kelsen
A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Cancer 1996;78(9):1988-95.
1996: Gary K Schwartz
Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations.
Seminars in oncology 1996;23(3):316-24.
1996: David P Kelsen; Martin S Karpeh; Gary K Schwartz; Hans Gerdes; C Lightdale; J Botet; G Lauers; David S Klimstra; Y Huang; Leonard B Saltz; V Quan; Murray F Brennan
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1818-28.
1995: Gary K Schwartz; Adriana Haimovitz-Friedman; S K Dhupar; Desiree Ehleiter; Peter Maslak; L Lai; F Loganzo; David P Kelsen; Zvi Fuks; Anthony P Albino
Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.
Journal of the National Cancer Institute 1995;87(18):1394-9.
1995: Y Nabeya; F Loganzo; Peter Maslak; L Lai; A R de Oliveira; Gary K Schwartz; M L Blundell; NK Altorki; David P Kelsen; A P Albino
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
International journal of cancer. Journal international du cancer 1995;64(1):37-46.
1995: Gary K Schwartz; Ephraim S Casper
A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma.
Investigational new drugs 1995;13(1):77-82.
1994: Leonard B Saltz; Nancy Kemeny; Gary K Schwartz; David P Kelsen
A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.
Cancer 1994;74(3):958-61.
1994: Gary K Schwartz; H Wang; N Lampen; NK Altorki; David P Kelsen; Anthony P Albino
Defining the invasive phenotype of proximal gastric cancer cells.
Cancer 1994;73(1):22-7.
1994: Gary K Schwartz
c-sis and oncogene expression: a fundamental approach toward understanding esophageal cancer.
Cancer investigation 1994;12(2):266-7.
1993: Ephraim S Casper; K L Christman; Gary K Schwartz; B Johnson; Murray F Brennan; Joseph R Bertino
Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma.
Cancer 1993;72(3):766-70.
1993: NK Altorki; Gary K Schwartz; M Blundell; B M Davis; David P Kelsen; Anthony P Albino
Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential.
Cancer 1993;72(3):649-57.
1993: K Christman; Leonard B Saltz; Gary K Schwartz; C Friedrich; David P Kelsen
Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression?
Journal of the National Cancer Institute 1993;85(10):826-7.
1993: Bruce D Minsky; Alfred M Cohen; Nancy Kemeny; Warren E Enker; David P Kelsen; Gary K Schwartz; Leonard B Saltz; J Dougherty; J Frankel; J Wiseberg
Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.
International journal of radiation oncology, biology, physics 1993;25(5):821-7.
1993: H W Bruckner; Shalom Kalnicki; J Dalton; H Snady; Gary K Schwartz; M R Chesser; D Lehrer; John Mandeli; N Harpaz; C Janus
Survival after combined modality therapy for pancreatic cancer.
Journal of clinical gastroenterology 1993;16(3):199-203.
1993: Gary K Schwartz; J Jiang; David P Kelsen; Anthony P Albino
Protein kinase C: a novel target for inhibiting gastric cancer cell invasion.
Journal of the National Cancer Institute 1993;85(5):402-7.
1993: SC Parisier; C J Agresti; Gary K Schwartz; J C Han; Anthony P Albino
Alteration in cholesteatoma fibroblasts: induction of neoplastic-like phenotype.
The American journal of otology 1993;14(2):126-30.
1993: H W Bruckner; Shalom Kalnicki; J Dalton; Gary K Schwartz; M R Chesser; John Mandeli; C Janus
Combined modality therapy increasing local control of pancreatic cancer.
Cancer investigation 1993;11(3):241-6.
1992: Ephraim S Casper; Gary K Schwartz; B Johnson; David P Kelsen
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.
Investigational new drugs 1992;10(4):313-6.
1992: Ephraim S Casper; Gary K Schwartz; David P Kelsen
Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.
Investigational new drugs 1992;10(3):205-9.
1992: Gary K Schwartz; J J Collins; A Galazka; P A Nessi; D Lehrer; Y Baldwin; John Mandeli; J F Holland
Phase I study of subcutaneously-administered bacterially-synthesised recombinant human granulocyte-macrophage colony-stimulating factor.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):470-3.
1991: Gary K Schwartz; H Arkin; James F Holland; T Ohnuma
Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate.
Cancer research 1991;51(1):55-61.
1990: Gary K Schwartz; S M Redwood; T Ohnuma; J F Holland; Michael J Droller; BC Liu
Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine.
Journal of the National Cancer Institute 1990;82(22):1753-6.